Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12731902 | 0.86 | — | — | |
| SCHEMBL26288474 | 0.82 | CYP1A2 (0.33) | PAK4 | |
| SCHEMBL15292260 | 0.82 | — | — | |
| SCHEMBL802214 | 0.82 | — | — | |
| SCHEMBL17997480 | 0.78 | — | — | |
| SCHEMBL12456245 | 0.71 | PAK4 (0.35) | PAK4 | |
| SCHEMBL11978470 | 0.71 | PAK4 (0.35) | PAK4 | |
| SCHEMBL23400626 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL10183422 | 0.71 | COMT (0.36) | — | |
| SCHEMBL17997479 | 0.71 | OGA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2023-01-03 | — | — | US | disclosed |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-10517872-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-12-31 | — | — | US | disclosed |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-9624246-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624246-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20160229871-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229871-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | PAK4 583/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | PAK4 1107/4885 |
| US-10517872-B2 | Pyridazinone macrocycles as IRAK inhibitors and uses thereof | IRAK2, IRAK1, IRAK3 | PAK4 583/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | PAK4 227/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | PAK4 227/4885 |
| US-11541041-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | PAK4 227/4885 |
| US-20170173019-A1 | PYRIDAZINONE MACROCYCLES AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK1, IRAK3 | PAK4 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.